Coronary Artery DiseaseCtaCABNCT07769008

CCTA-Based vs CAG-Based CABG: A Multicenter Pragmatic Non-Inferiority Trial

A study testing CCTA-based CABG and CAG-based CABG in people with Coronary Artery Disease and Coronary Artery Bypass Grafting, run by Ruijin Hospital at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

The goal of this clinical trial is to find out if using a non-invasive heart scan (called coronary computed tomography angiography, or CCTA) to plan coronary artery bypass grafting (CABG) works as well as the standard invasive approach (called coronary angiography, or CAG) for people with blocked heart arteries. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Coronary Artery Disease, Coronary Artery Bypass Grafting, Coronary Computed Tomography Angiography
What is being tested?: CCTA-based CABG and CAG-based CABG
Type of treatment: Surgery or procedure
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 826 participants
Where: 1 siteChina
Study dates: 17 Aug 2026to Aug 2029
Phase: Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Referred to CABG treatment

Who cannot join

Under the age of 18 years
Unable to provide informed consent
Emergency CABG
Redo-CABG
Prior PCI with coronary stent implantation
Cardiogenic shock

Show all 10Show fewer

Unable to undergo CAG or CCTA examination or deemed unsuitable by the investigator, such as:
Known allergy to iodinated contrast media; Active hyperthyroidism or uncontrolled thyroid disease; Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m²; Atrial fibrillation with rapid ventricular response or severe arrhythmias not amenable to rate control;
Pregnancy, lactation, or childbearing potential without effective contraception in female participants
Concurrent participation in another interventional trial

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Yunpeng Zhu, MD contact

0086-02164370045

zyp12220@rjh.com.cn

China1 site, 1 recruiting

Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai
Yunpeng Zhu, MD, 0086-02164370045, zyp12220@rjh.com.cn
Yunpeng Zhu, MD
Recruiting

Other trials in China

About this study

Official title: Coronary Computed Tomography Angiography-Based Versus Coronary Angiography-Based Coronary Artery Bypass Grafting: A Multicenter Pragmatic Non-Inferiority Randomized Controlled Trial

The main questions it aims to answer are:

Do people who have surgery planned with the non-invasive heart scan have similar health outcomes at 1 year as those who have surgery planned with the standard invasive approach? How does the non-invasive approach compare in terms of heart attacks, strokes, unplanned repeat procedures, and longer hospital stays? Researchers will compare two groups of participants. One group will have their surgery planned using only the CCTA . The other group will have their surgery planned using only the CAG. Both groups will undergo the CABG per local protocol.

Participants will:

Be randomly assigned (like flipping a coin) to one of the two planning approaches Undergo CABG as scheduled Return for follow-up visits at sugery days, 7 days, 1 month, 6 months, and 1 year after surgery Have a follow-up CCTA scan at 7 days and 1 year to check if the new bypass grafts are working well

Conditions: Coronary Artery Disease, Coronary Artery Bypass Grafting, Coronary Computed Tomography Angiography, Coronary Angiography (CAG)
Being tested: CCTA-based CABG, CAG-based CABG
Keywords: Major Adverse Cardiovascular Events (MACE), Coronary Artery Bypass Grafting (CABG), Coronary Computed Tomography Angiography(CCTA), Coronary Angiography(CAG)
Medical subject headings: Coronary Artery Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

CCTA-based CABGProcedure or surgery
Surgical planning based solely on CCTA-derived data, including diameter stenosis (DS), area stenosis (AS), CT-derived fractional flow reserve (CT-FFR), LV:RV perfusion index, plaque characterization, 3D reconstruction of target vessels, and collateral circulation of chronic total occlusions (CTO) and so on.
CCTA performed using photon-counting CT or conventional CT (≥64-slice, preferably ≥256-slice), following a standardized acquisition protocol. Images are transferred to an independent core laboratory for quantitative analysis and standardized reporting.
The operating surgeon will not have access to CAG.
CAG-based CABGProcedure or surgery
Surgical planning following standard practice using invasive coronary angiography(CAG). Angiograms obtained using a flat-panel detector system with standardized projections. The results of CAG are interpreted by the operating surgeon.The operating surgeon will not have access to CCTA.

Study groups in NCT07769008
Study group	Role	What they receive
CCTA-Based CABG	Experimental	Not described Receives: Procedure: CCTA-based CABG
CAG-Based CABG	Active comparator	Not described Receives: Procedure: CAG-based CABG

What is being measured

The primary outcome is the main question the study is designed to answer.

1-year incidence of 5-Point Major Adverse Cardiovascular Events (5P-MACE)
The 5P-MACE was defined as a composite of all-cause death, myocardial infarction, stroke, unplanned revascularization, and CABG-related or cardiovascular-related prolonged postoperative length of stay (PLOS) or rehospitalization.
Measured: Within 1 year post-CABG

Secondary outcomes (10)

1-year incidence of all-cause death
Measured: Within 1 year post-CABG
1-year incidence of CV death
Measured: within 1 year post-CABG
1-year incidence of MI
Measured: Within 1 year post-CABG
1-year incidence of stroke
Measured: Within 1 year post-CABG
1-year incidence of unplanned revascularization
Measured: Within 1 year post-CABG
1-year incidence of CABG-related or CV-related prolonged PLOS or rehospitalization.
Measured: Within 1 year post-CABG
30-day incidence of the operative mortality and morbidity
The operative mortality and morbidity was defined as a composite of all-cause death, myocardial infarction, stroke, unplanned revascularization, cardiac arrest, reoperation, prolonged ventilation, deep sternal wound infection, pacemaker implantation, major gastrointestinal bleeding, and new dialysis .
Measured: Within 30 days post-CABG
7-day graft failure rate
Graft failure defined as modified FitzGibbon grade B, S, or O, assessed by CCTA.
Measured: At 7 day post-CABG
1-year graft failure rate
Graft failure defined as modified FitzGibbon grade B, S, or O, assessed by CCTA.
Measured: At 1 year post-CABG
Other serious adverse events (SAE)
Important medical events that impact subjects' daily life or health and require appropriate intervention, but are not part of the primary or secondary outcome definitions above
Measured: Within 1 year post-CABG

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

17 Aug 2026Aug 2029

First posted17 Aug 2026
Study start17 Aug 2026
Primary completionAug 2029 (estimated)
Study completionAug 2029 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
More trials run by Ruijin HospitalThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Outcomes assessor
Enrolment: 826 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07769008
Sponsor's protocol ID: KY-2026-523
Acronym: CtaCAB
Status last verified: Aug 2026
First submitted: 10 Aug 2026
Last updated: 19 Aug 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Interested in taking part?

Yunpeng Zhu, MD

0086-02164370045

zyp12220@rjh.com.cn

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Active, not recruitingObservational study
The DISCOVER INOCA Prospective Multi-center Registry
Ischemia and No Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction
RecruitingPhase 4
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Active, not recruiting
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions
Coronary Artery Disease, Atherosclerosis of Coronary Artery
Not yet recruiting
The CORE Platform Trial
Coronary Revascularization, Coronary Artery Disease
Active, not recruiting
Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS
Coronary Artery Disease, Coronary Disease

All Coronary Artery Disease trials